LSE:GSKPharmaceuticals
GSK China Hepatitis B Push Raises Questions For Valuation And Dividend Risks
GSK (LSE:GSK) has entered an exclusive collaboration with Sino Biopharmaceutical, focused on bepirovirsen, a potential first in class hepatitis B treatment for the Chinese market.
The partnership aims to accelerate the launch of bepirovirsen in China, targeting a large population affected by chronic hepatitis B.
The agreement combines GSK’s R&D in hepatitis B with Sino Biopharmaceutical’s local healthcare presence to expand patient access.
For GSK, which is focused on vaccines and specialty...